Search

Search Constraints

You searched for: Author/Creator Pusceddu, S

Search Results

2. 1308OActivity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). (23rd October 2018)

3. 1324PThe role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs). (23rd October 2018)

4. Clinico–pathological features, treatments and survival of malignant insulinomas: a multicenter study. Issue 4 (April 2020)

5. Clinico–pathological features, treatments and survival of malignant insulinomas: a multicenter study. Issue 4 (April 2020)